
From the archive. Published on 13 March 2021 and not updated since. Figures and job titles may have changed.
THD NewsDesk, New Delhi: According to real world data, as published by the pharma company, Pfizer-BioNtech’s Covid-19 vaccine offers at least 97 per cent effectiveness in symptomatic Covid-19 cases.
Vaccine provides effectiveness against 94 per cent against asymptomatic SARS-CoV-2 infections as per the analysis based on real world data gathered by the Israel Ministry of Health. “As demonstrated in our Phase 3 clinical trial, we are extremely encouraged to announce that the real-world effectiveness data coming from Israel are confirming the high efficacy and showing the significant impact of inorder to prevent severe disease and deaths due to Covid-19” said Luis Jodar, Senior Vice President and Pfizer Vaccines, Chief Medical Officer said in a statement.
To monitor the real-world impact of the Pfizer-BioNTech Covid-19 vaccine, Pfizer and the Israel MoH entered into a collaboration agreement in January.
This comprehensive real-world evidence can be of importance to countries around the world as they advance their own vaccination campaigns one year after the World Health Organization (WHO) declared Covid-19 a pandemic.
For all outcomes, vaccine effectiveness was measured from two weeks after the second dose. The findings from the analysis were derived from de-identified aggregate Israel MoH surveillance data collected between January 17 and March 6, 2021.
Follow The Healthcare Daily on Google News
New stories appear where you already read the news.
The Healthcare Daily. We report from primary sources and list them on every story.


